A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

LifeVantage (LFVN) announced the completion of an international in vitro cell study that investigated the effects of its international ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

As “GLP-1 receptor agonists,” they mimic a naturally occurring hormone, GLP-1, released in the body after someone eats. For reasons that remain unclear, many patients that struggle with ...

It’s a synthetic version of the hormone GLP-1, which helps regulate our metabolism and hunger. Semaglutide and other newer GLP-1 medications have proven to be far more effective at treating ...

Recently, there has been a lot of buzz around GLP-1 weight loss injections. Talk of Ozempic or Wegovy has been hard to miss.

GLP-1, or glucagon-like peptide-1, is a hormone produced in the digestive system that regulates appetite and insulin secretion. Medications like Ozempic and Wegovy, categorized as GLP-1 agonists ...

SALT LAKE CITY - LifeVantage Corporation (NASDAQ:LFVN), a $271 million market cap player in the health and wellness sector with impressive 79% gross profit margins, today announced the successful ...

For GLP-1 patients hoping to lose weight while retaining ... Wang also notes that hormones tend to operate in cycles and that BCL6 naturally rises and falls with a strong circadian rhythm.

About one in eight adults in the United States has tried or currently uses a GLP-1 medication, and a quarter of those users cite weight loss as their main goal.